American Society of Hematology (ASH)

An interim analysis from the informCLL Real-World Registry found that most ibrutinib-treated patients started at the FDA-recommended once-daily dose of 420 mg, with few dose interruptions or reductions over time. Read More ›

The combination of ibrutinib and CTL119, an anti-CD19 CAR T-cell antibody, showed promising results in a pilot trial with ibrutinib, with a high rate of patients achieving minimal residual disease–negative status. Read More ›

Researchers report promising findings for patients treated with a venetoclax-rituximab combination regimen in relapsed/refractory chronic lymphocytic leukemia (CLL). Read More ›

New data suggest that adding obinutuzumab to ibrutinib in patients with chronic lymphocytic leukemia (CLL) may be effective at improving minimal residual disease (MRD) response rates, especially in patients with low tumor burden after prior ibrutinib therapy. Read More ›

The antibody-drug conjugate mirvetuximab soravtansine combined with pembrolizumab has a manageable safety profile and encouraging signals of clinical activity. Read More ›

The combination of brentuximab vedotin and ibrutinib was well-tolerated and resulted in an overall response rate of 69%, a complete response rate of 46%, and a disease control rate of 100% in patients with relapsed/refractory Hodgkin lymphoma. Read More ›

The preliminary results of a multicenter phase 1b dose-escalation study evaluated the safety, tolerability, and efficacy of 2 novel venetoclax-based combination therapies, in combination with the MEK inhibitor cobimetinib or the MDM2 inhibitor idasanutlin, in relapsed/refractory (R/R) acute myeloid leukemia (AML). Read More ›

In a cost-effectiveness and cost-utility analysis of ibrutinib versus allogeneic hematopoietic stem-cell transplantation (HSCT) in patients with relapsed/refractory CLL with del(17p), ibrutinib provides significantly greater clinical and economic value over the first 3 years of treatment, but the benefit declines beyond 3 years. Read More ›

Interim results of an ongoing phase 1 study showed that the addition of the selective FLT3 inhibitor quizartinib to azacitidine or low-dose cytarabine produced high overall response rates in patients with FLT3-ITD–mutated myeloid leukemias. Read More ›

The combination of ibrutinib plus nivolumab in patients with relapsed/refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma, follicular lymphoma, and diffuse large B-cell lymphoma was safe but not more effective than ibrutinib alone. It did, however, demonstrate superior efficacy in patients with Richter’s transformation, although the study did not select patients with elevated PD-L1 levels. Read More ›